Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA7 | P43166 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MMP3 | P08254 | 2/20 | 0.48 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NCF1 | P14598 | 2/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17167339 | 0.98 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3369633 | 0.92 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3401745 | 0.88 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4059980 | 0.86 | GAA (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23536326 | 0.85 | KDM4E (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29771215 | 0.84 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1189822 | 0.84 | CA12 (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL232895 | 0.84 | TSHR (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1169534 | 0.83 | CA12 (0.66) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6367290 | 0.83 | MMP3 (0.51) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252741-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20100105607-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2010048340-A2 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-7223779-B2 | Azasugar derivative and drug containing the same as the active ingredient | CARNA BIOSCIENCES INC. (JP) | 2007-05-29 | — | — | US | disclosed |
| EP-1188755-B1 | ACYLHYDRAZINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20050154017-A1 | Novel azasugar derivative and drug containing the same as the active ingredient | CARNA BIOSCIENCES INC. (JP) | 2005-07-14 | — | — | US | disclosed |
| US-20050137221-A1 | Novel azasugar derivative and drug containing the same as the active ingredient | TSUKIDA TAKAHIRO (JP) | 2005-06-23 | — | — | US | disclosed |
| EP-1516872-A1 | NOVEL AZASUGAR DERIVATIVE AND DRUG CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Carna Biosciences Inc. (JP) | 2005-03-23 | — | — | EP | disclosed |
| US-6723722-B1 | BLOOD COAGULATION FACTOR X INHIBITORS; ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-04-20 | — | — | US | disclosed |
| EP-1188755-A1 | ACYLHYDRAZINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154017-A1 | Novel azasugar derivative and drug containing the same as the active ingredient | CDK8, DUT, CDK7 | CA12 4135/4885CA1 4554/4885CA2 4105/4885 |
| US-20100105607-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | ASNS, ALG8, ALG1 | CA12 993/4885CA1 2552/4885CA2 3594/4885 |
| US-20050137221-A1 | Novel azasugar derivative and drug containing the same as the active ingredient | CDK8, DUT, CDK7 | CA12 4135/4885CA1 4554/4885CA2 4105/4885 |
| US-20120252741-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | ASNS, DNPEP, ALG8 | CA12 767/4885CA1 2394/4885CA2 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.